Get Live Data

The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Scancell Holdings Share Price
  4. Scancell Holdings Share News
  5. UK Earnings, Trading Statements Calendar - Next 7 Days

Pin to quick picksScancell Holdings Share News (SCLP)

Scancell Holdings Information

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.55
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (5.376%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.55
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Earnings, Trading Statements Calendar - Next 7 Days

Tue, 18th Sep 2018 16:19

Wednesday 19 September 
KingfisherHalf Year Results
Babcock InternationalTrading Statement 
Stagecoach GroupTrading Statement 
RA InternationalHalf Year Results
Yu GroupHalf Year Results
Alliance PharmaHalf Year Results
Cello Health GroupHalf Year Results
Accesso TechnologyHalf Year Results
Greencoat RenewablesHalf Year Results
ErgomedHalf Year Results
QuixantHalf Year Results
EKFHalf Year Results
Thursday 20 September 
IG GroupQ1 Results
Kier GroupHalf Year Results
SOCO InternationalHalf Year Results
Safestyle UKHalf Year Results
City PubHalf Year Results
hVIVOHalf Year Results
LamprellHalf Year Results
Brooks Macdonald GroupFull Year Results
ScisysHalf Year Results
Venture Life GroupHalf Year Results
Inland HomesFull Year Results
Modern WaterHalf Year Results
French ConnectionHalf Year Results
FW ThorpeFull Year Results
Friday 21 September 
Smiths GroupFull Year Results
SIGHalf Year Results
M&C SaatchiHalf Year Results
Triple Point Social HousingHalf Year Results
New Star Investment TrustFull Year Results
Monday 24 September 
Pennon GroupTrading Statement 
Gama AviationHalf Year Results
XLMediaHalf Year Results
KapeHalf Year Results
MaxcyteHalf Year Results
InstemHalf Year Results
Trinity ExplorationHalf Year Results
River & Mercantile GroupFull Year Results
DeltexHalf Year Results
Tuesday 25 Setember 
NextHalf Year Results
AG BarrHalf Year Results
Close BrothersFull Year Results 
OsiriumHalf Year Results
FireAngel SafetyHalf Year Results
Card FactoryHalf Year Results
S&UHalf Year Results
Keystone LawHalf Year Results
Altitude GroupHalf Year Results
Animalcare GroupHalf Year Results
EbiquityHalf Year Results
Menhaden CapitalHalf Year Results
WANdiscoHalf Year Results
Mortgage Advice BureauHalf Year Results
Learning TechnologiesHalf Year Results
Thomas Cook GroupTrading Statement 
United UtilitiesTrading Statement 
Hotel Chocolat GroupFull Year Results 
Harvey Nash GrouipHalf Year Results
Moss BrosHalf Year Results
SSEFinancial Outlook Statement
Blancco Technology GroupFull Year Results 
ScancellFull Year Results 
  

More News
31 Oct 2022 16:46

Scancell enrols and doses first patient in latest cancer trial

(Sharecast News) - Immunotherapy developer Scancell announced on Monday that the first patient in the expansion phase of the monotherapy arms in the multicentre phase one clinical trial of 'Modi-1', dubbed 'ModiFY', had been enrolled and dosed.

Read more
28 Oct 2022 14:42

Scancell losses widen on expense of ongoing trials

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to the expense of its three ongoing clinical trials.

Read more
28 Oct 2022 11:57

IN BRIEF: Scancell narrows annual loss as vaccine candidates progress

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - In the year that ended April 30, pretax loss narrows to GBP3.8 million from GBP16.8 million a year before. Records no revenue in either year. Spends more on development and administration, which is offset by a gain of GBP7.2 million on substantial modification of convertible loan notes, compared to no such gain in the previous year. Expects early safety and efficacy data from the ModiFY study in the coming year.

Read more
26 Oct 2022 14:30

IN BRIEF: Scancell executive chair and co-founder both to depart

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Both the executive chair and the company's co-founder will leave the board, while Scancell promotes a non-executive director to deputy chair. Lindy Durrant, also a co-founder, remains chief executive officer. John Chiplin will step down as executive chair and as a director once a new chair is found, having led the board for six years. Richard Goodfellow will retire as non-executive director at the next annual general meeting. Scancell holds its AGMs in November. Goodfellow is a co-founder of Scancell and was its CEO until 2017. Susan Clement Davies will be deputy chair.

Read more
25 Oct 2022 14:34

Scancell inks licensing deal with Nasdaq-traded Genmab

(Sharecast News) - Immunotherapy developer Scancell announced a licensing agreement with the Nasdaq-listed Genmab on Tuesday, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products.

Read more
25 Oct 2022 12:17

LONDON MARKET MIDDAY: Sterling strength keeps FTSE 100 in red

(Alliance News) - Stocks were mixed in London in midday trade on Tuesday, with the FTSE 100 suffering a bit against a strong pound, which is getting support as Rishi Sunak takes control in Westminster.

Read more
25 Oct 2022 10:44

AIM WINNERS & LOSERS: Scancell signs deal; Empire Metals seeks copper

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
25 Oct 2022 10:03

Scancell shares rocket on potentially lucrative Genmab licensing deal

(Alliance News) - Scancell Holdings PLC shares soared on Tuesday, as the cancer immunotherapies developer announced a licensing agreement with biotechnology company Genmab.

Read more
23 Sep 2022 13:31

Scancell presents new, positive data on possible cancer therapies

(Sharecast News) - Immunotherapy developer Scancell was presenting two posters at the EuroMAbNet 12th annual meeting in Hamburg on Friday, with the first highlighting new data on its 'AvidiMab' and 'GlyMab' technologies.

Read more
16 Aug 2022 17:51

IN BRIEF: Scancell doses first patient in Modi-1 cancer trial

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says first patient is dosed in cohort two of the multicentre phase I Modify trial, for Modi-1, its prospective cancer treatment. The trial will administer Modi-1 alone or with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours. Modi-1 is the first candidate from the firm's Moditope platform.

Read more
23 Jun 2022 21:28

TRADING UPDATES: FirstGroup extends takeover date; Tasty repays debt

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
23 Jun 2022 12:38

Scancell developing 'promising' new cancer treatment approach

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic as a "promising new therapeutic approach" to treat cancer.

Read more
15 Jun 2022 15:58

Scancell updates protocol for UK trial in melanoma patients

(Sharecast News) - Immunotherapy developer Scancell updated the market on the phase 2 'SCOPE' clinical trial in melanoma patients on Wednesday, being conducted at multiple centres in the UK.

Read more
15 Jun 2022 12:19

Scancell shares jump as phase 2 trial of skin cancer drug expands

(Alliance News) - Scancell Holdings PLC on Wednesday said its phase 2 trial of its SCIB1 vaccine in metastatic melanoma patients has expanded, following regulatory approval.

Read more
13 Jun 2022 20:42

IN BRIEF: Scancell says first patient dosed in Modi-1 trial for cancer

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says the first patient in its multicentre Modi-1 clinical trial has been dosed at Imperial College London, Hammersmith Hospital. The study, it explains, is a first-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer. Modi-1 will be administered alone or in combination with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours.

Read more
12345678910

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.